What are the recommended treatment options for a vancomycin‑resistant Enterococcus faecium infection?

Treatment of Vancomycin-Resistant Enterococcus faecium (VRE)

Linezolid 600 mg IV or PO every 12 hours is the first-line treatment for VRE E. faecium infections, with the strongest recommendation across all infection sites. 1

Site-Specific Treatment Algorithm

Bacteremia/Bloodstream Infections

• First-line: Linezolid 600 mg IV/PO q12h for 10-14 days (Strong recommendation, 1C) 1
• Alternative: High-dose daptomycin 8-12 mg/kg/day IV (Weak recommendation, 2C) 1
  • Consider adding beta-lactams (penicillins, carbapenems, or cephalosporins except cefotaxime/cefazolin) if daptomycin MIC is 3-4 mg/mL 1
  • Daptomycin showed lower mortality (32.8%) compared to daptomycin alone (35.7%) in meta-analysis, though with significant heterogeneity 1

Critical caveat: For infective endocarditis, cardiac surgery combined with antimicrobial therapy should be considered 1

Intra-abdominal Infections

• First-line: Linezolid 600 mg IV/PO q12h for 5-7 days (Strong recommendation, 1C) 1
• Alternative: Tigecycline 100 mg IV loading dose, then 50 mg IV q12h (Weak recommendation, 2D) 1
  • Tigecycline showed 97.6% overall success rates in observational studies 1

Pneumonia

• Treatment: Linezolid 600 mg IV q12h for at least 7 days (Strong recommendation, 1C) 1

Complicated Urinary Tract Infections

• First-line: Linezolid 600 mg IV/PO q12h for 5-7 days (Strong recommendation, 1C) 1
• Alternative: Daptomycin 6-12 mg/kg IV daily for 5-7 days (Weak recommendation, 2D) 1

Uncomplicated Urinary Tract Infections

Multiple narrow-spectrum options available (all Weak recommendations, 2D) 1:

• Fosfomycin: 3 g PO single dose (or every other day)
• Nitrofurantoin: 100 mg PO four times daily for 3-7 days
• High-dose ampicillin: 18-30 g/day IV in divided doses for 3-7 days
• Amoxicillin: 500 mg PO/IV q8h for 3-7 days

Important note: Despite VRE designation, 82% of E. faecalis VRE isolates remain ampicillin-susceptible 2. High urinary concentrations of ampicillin can overcome high MICs in UTIs 1. One study showed 88.1% clinical eradication with ampicillin for ampicillin-resistant VRE UTIs 1.

Key Evidence Considerations

Linezolid vs. Daptomycin Debate

The evidence shows conflicting mortality data:

• One meta-analysis showed linezolid mortality of 32.8% vs. daptomycin 35.7% (RR 1.24, p=0.03) 1
• However, a second analysis found no significant difference in 1-month mortality (34.1% vs. 33.1%, p=0.36) 1
• Microbiological cure rates were comparable: 91% for linezolid vs. 93% for daptomycin 1

Clinical interpretation: Despite mixed mortality data, linezolid receives the only strong recommendation (1C) across all infection sites, while daptomycin receives weak recommendations (2C-2D) 1. This reflects linezolid's FDA approval for VRE (2000) versus daptomycin's off-label use 1.

Emerging Resistance Concerns

• Linezolid resistance has been reported due to 23S ribosome binding site mutations 3
• Daptomycin resistance emergence during therapy is documented 4
• Recent case reports describe successful salvage therapy with oritavancin for multidrug-resistant VRE when both linezolid and daptomycin failed 4

Critical Pitfalls to Avoid

1. Don't treat colonization: Differentiate true infection from colonization before initiating anti-VRE therapy 1. VRE colonization prevalence in ICUs ranges from 5.8-8% at admission 1.

2. Source control is paramount: Remove central lines, drain abscesses, and address surgical sources before expecting antimicrobial success 5, 3.

3. Avoid empiric broad-spectrum overuse: Despite 82% ampicillin susceptibility in VRE E. faecalis, daptomycin remains the most commonly used agent (19%), representing poor antimicrobial stewardship 2.

4. Monitor for adverse effects:

   • Linezolid: Thrombocytopenia (especially >14-21 days), GI symptoms, headache 3
   • Daptomycin: Myalgia, elevated CPK, requires monitoring 2
   • Tigecycline: Lower serum levels may limit use in bacteremia 1

5. Duration matters: Treatment duration should be individualized based on infection site, source control, comorbidities, and clinical response 1. The guideline provides specific durations: 10-14 days for bacteremia, 5-7 days for IAI/cUTI, at least 7 days for pneumonia 1.